# A Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function

> **NCT03799848** · PHASE1 · COMPLETED · sponsor: **Akebia Therapeutics** · enrollment: 24 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** Vadadustat

## Key facts

- **NCT ID:** NCT03799848
- **Lead sponsor:** Akebia Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-12
- **Primary completion:** 2018-10-18
- **Final completion:** 2018-10-18
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2019-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03799848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03799848, "A Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03799848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*